# Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers

> **NCT04788459** · PHASE1,PHASE2 · TERMINATED · sponsor: **Takis** · enrollment: 68 (actual)

## Conditions studied

- COVID-19
- Protection Against COVID-19 and Infections With SARS-CoV- 2
- COVID-19 Immunisation

## Interventions

- **BIOLOGICAL:** COVID-eVax
- **DEVICE:** Cliniporator® and EPSGun

## Key facts

- **NCT ID:** NCT04788459
- **Lead sponsor:** Takis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-25
- **Primary completion:** 2021-12-07
- **Final completion:** 2021-12-07
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** The good progress of the Italian national vaccination campaign against COVID-19 made impossible to complete the study as planned.
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04788459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04788459, "Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04788459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*